These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38485223)

  • 1. Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection.
    Sanson C; Roosen A; Faron M; Zaccarini F; Maulard A; Scherier S; Pautier P; Leary A; Chargari C; Espenel S; Genestie C; Morice P; Gouy S
    Int J Gynecol Cancer; 2024 May; 34(5):730-737. PubMed ID: 38485223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
    Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
    Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of diaphragm involvement in stage 3B/3C ovarian-tubal-peritoneal epithelial cancer patients and survival outcomes.
    Durmuş Y; İşçi Bostancı E; Duru Çöteli AS; Ünsal M; Kayıkçıoğlu F; Boran N
    Arch Gynecol Obstet; 2021 Jan; 303(1):241-248. PubMed ID: 32989507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
    Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
    [No Abstract]   [Full Text] [Related]  

  • 15. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer.
    Yoshino Y; Taguchi A; Takao M; Kashiyama T; Furusawa A; Uno M; Okada S; Kino N; Yasugi T
    Int J Clin Oncol; 2019 Apr; 24(4):428-436. PubMed ID: 30506281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Shaalan W; Elemam D; Mansour H; Melis M; Malik E; Soliman AA
    J Gynecol Oncol; 2018 Jul; 29(4):e47. PubMed ID: 29770618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
    Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
    Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.